Data from a large retrospective cohort study suggested that, diabetic patients treated with three commonly prescribed sulfonylurea drugs had a 50% higher mortality risk compared with patients treated with metformin….
Read More »Stop Using Sulfonylureas?
The ACP has issued a clinical practice guideline regarding use of oral agents in type 2 diabetes entitled, “Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians.”… This is important because despite new therapies, there hasn’t been a guideline from either …
Read More »Heart Risk Higher in Those Taking Sulfonylurea Drugs vs. Metformin
This retrospective study looking at data from an electronic health record database found that older patients with type 2 diabetes who started treatment with sulfonylurea (SU) drugs were significantly more likely to experience CVD than those who started with metformin….
Read More »Higher Risks of Death and Heart Failure Tied to Sulfonylureas
Sulfonylurea monotherapy for Type 2 diabetes was associated with increased risks of all-cause death and congestive heart failure compared with metformin, a large, retrospective study showed.
Read More »ADA – GLP-1 Liraglutide Versus Sulfonylureas
Novo Nordisk experimental diabetes drug liraglutide was significantly better at helping patients control blood sugar than an older common medicine after two years of treatment, according to data from a clinical trial.
Read More »Hypoglycemia More Common With Sulfonylurea Than With Metformin Use
Among patients with type 2 diabetes taking oral antidiabetes drugs, hypoglycemia is nearly 3 times more common with sulfonylurea treatment than with metformin use
Read More »Mechanism For Sulfonylurea Treatment Failure In Type 2’s
In a set of mouse experiments, scientists attempt to learn more about why sulfonylureas eventually fail in the treatment of patients with type 2 diabetes. They may be more likely to keep working if they are used in moderation and stopped for a period of time.
Read More »Octreotide Ameliorates Sulfonylurea-Induced Hypoglycemia
Administration of octreotide (brand name Sandostatin, Novartis Pharmaceuticals) increases serum glucose levels in patients with sulfonylurea-induced hypoglycemia, according to a report in the April Annals of Emergency Medicine.
Read More »Sitagliptin (Januvia) Plus a Sulfonylurea Increases Risk for Hypoglycemia
The FDA approved safety labeling revisions for sitagliptin tablets (Januvia; Merck & Co, Inc) to advise of the risk for hypoglycemia. With Januvia’s newly approved uses as add-on therapy with a sulfonylurea (glimepiride) when the single agent alone does not provide adequate glycemic control and add-on therapy to glimepiride and …
Read More »More Evidence of Cardiovascular Safety of Second-Generation Sulfonylureas
Diabetes patients who used second-generation sulfonylureas had no excess one-year mortality after a myocardial infarction, researchers said….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.